NCT00056160 · OUTCOME

Overall Survival

CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma · Source last updated 2017-10-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: Weeks
Interval / dispersion: 95% Confidence Interval
Time frame: 170 weeks (median overall survival of CC-5013/Dex treatment group)

What was measured

Overall survival was calculated as the time from randomization to death from any cause.

Analysis population: Analysis conducted on the Intent-To-Treat (ITT) Population. The ITT Population was defined as all subjects randomized.

CC-5013 (lenalidomide) plus oral high-dose dexamethasone

Placebo, identical in appearance to CC-5013 (lenalidomide), plus oral high-dose dexamethasone

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
CC-5013/Dex	177
Placebo/Dex	176

Source class 1

Values in Weeks · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
CC-5013/Dex	170.1	Not reported	142.1	204.9	Not reported
Placebo/Dex	136.4	Not reported	104.1	176.9	Not reported

Complete source fields

classes

denoms

description

Overall survival was calculated as the time from randomization to death from any cause.

dispersion Type

95% Confidence Interval

groups

param Type

MEDIAN

population Description

Analysis conducted on the Intent-To-Treat (ITT) Population. The ITT Population was defined as all subjects randomized.

reporting Status

POSTED

time Frame

170 weeks (median overall survival of CC-5013/Dex treatment group)

title

Overall Survival

type

SECONDARY

unit Of Measure

Weeks

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice